15 December 2017
EFPIA Japan

EFPIA Japan re-elected Ole Mølskov Bech as Chairman
for the coming two year periodTOKYO—15 December 2017— EFPIA Japan announced today that Ole Mølskov Bech(President and Representative Director, Novo Nordisk Japan Ltd.) was re-elected asChairman of EFPIA Japan for the period from 1 January 2018 to 31 December 2019.
Philippe Fauchet (GlaxoSmithKline K.K.) and Thorsten Poehl (Nippon Boehringer
Ingelheim Co., Ltd.) will continue to serve in their positions as Vice Chairmen and will
support Ole Mølskov Bech together with 6 other Board Directors. Along with this,Yoshitada Kimura (Novo Nordisk Japan Ltd.) and Rie Nakanishi (Novo Nordisk JapanLtd.) are appointed as new Director General and new Secretary General respectively.
The EFPIA Japan office will move to a new office in Novo Nordisk Pharma Ltd. Tokyo
home office in Marounuchi.
“The changes in the drug pricing policy announced on November 22 will lead to significant
changes in the business environment for research-driven global pharmaceuticalcompanies”, says Ole Mølskov Bech, the Chairman of EFPIA Japan. “In order to ensure
Japanese patient continue to have access to new innovate medicines as early as the restof the world, EFPIA Japan will actively engage in transparent and constructive dialogue
with the government and other stakeholders to facilitate the policy changes that are mostharmful to innovation will be revisited.
EFPIA Japan Board Members as of 1 January 2018
Newly appointed board members during this year are noted
ChairmanOle Mølskov Bech (Novo Nordisk Japan Ltd.)
Vice Chairmen
Philippe Fauchet (GlaxoSmithKline K.K.)
Thorsten Poehl (Nippon Boehringer Ingelheim Co., Ltd.)
DirectorsJacques Nathan (Sanofi K.K.)
Heike Prinz (Bayer Yakuhin, Ltd.)
Kazunari Tsunaba (Novartis Pharma K.K.)
Marc Dunoyer (AstraZeneca K.K.)
Stefan Sakurai (LEO Pharma K.K.)
Christopher Hourigan (Janssen Pharmaceutical K.K.)
New
Director General
Yoshitada Kimura (EFPIA Japan and Novo Nordisk)
New
Secretary General Rie Nakanishi (EFPIA Japan and Novo Nordisk)New__________________________________________________________________EFPIA Japan Office
Marunouchi Kitaguchi Bldg., 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8265
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

New EFPIA Japan Office (Effective from January 1, 2018)
Meiji Yasuda Seimei Bldg., 2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Tel: +81-3-6266-1354 Fax: +81-3-6266-1819
About EFPIA Japan:
Established in April 2002, EFPIA Japan represents 24 R&D-based European
pharmaceutical companies operating in Japan. In 2016, combined sales from the member
companies accounted for roughly 22% of the pharmaceutical market in Japan.
Mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan by early
introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen
dialogue with decision-makers in order to improve Japanese healthcare for all.
About EFPIA:EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents
the pharmaceutical industry operating in Europe. Through its direct membership of 33
national associations and 42 leading pharmaceutical companies, EFPIA provides thevoice of 1,900 companies committed to researching, developing and bringing new
medicines to improve health and quality of life around the world.
For more information please visit:
http://www.efpia.eu (EFPIA)
http://efpia.jp/English/index-e.html (EFPIA Japan)

Inquiries to:
Noriko Okazaki, Committee Chair, Public Relations Committee, EFPIA Japan
Novo Nordisk Pharma Ltd.
2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005
TEL: 080-3508-3251
Mail: no@novonordisk.com
Tetsu Owari, Committee Vice Chair, Public Relations Committee, EFPIA Japan
Boehringer Ingelheim Japan, Inc.
ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017
TEL: 03-6417-2223
Mail : tetsuya.owari@boehringer-ingelheim.com

2